My good friend and fellow advocate Mike Scott (Prostate Cancer Info Link) introduced me to a new web site produced by the University of Chicago called Cost of Care (www.CostofCare.org). The site is designed around the novel idea that the cost we must pay for our cancer care has become another negative side effect or [...]
Clinical trials are vital if we expect to continue to see improvements in the treatments and medications that are available. Unfortunately, there are some historical abuses in clinical trials so many people do approach them with a level of distrust. In contemporary times the clinical trial system has many safeguards that did not exist even [...]
In an online article published Friday, November 6, 2015 Dr. David Crawford raises some very serious questions about how we standardly use hormone therapy (ADT) in the treatment of men with advanced prostate cancer. He claimed that not only is it vital for initial positive outcomes, it is vital for the successful use of the [...]
It has been long assumed that hormone therapy (ADT) used in the treatment of men with advanced prostate cancer increases a man’s risk for developing potentially live threatening thromboembolic disease (formation in a blood vessel of a clot (thrombus) that breaks loose and is carried by the blood stream to plug another vessel. The clot [...]
The Response Evaluation Criteria In Solid Tumors (RECIST) was first published in 2000 and then updated in 2009. RECIST is a set of published rules that attempt to define when cancer tumors, including prostate cancer tumors, improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. This criteria has become very important as the majority [...]